You are about to leave the Clinical Value website now.

Cancel

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

Meta-analysis of biomarkers for HCC diagnosis, including AFP, DCP (PIVKA-II), GPC3, GP73, Hsp90alpha, midkine, and OPN

Quick Summary

Hepatocellular carcinoma lacks ideal diagnostic biomarkers. There is a lack of scientific evaluation of relevant promising biomarkers as well. Therefore this study reanalyzes the related studies of 11 blood biomarkers of HCC, and compares the diagnostic value of these biomarkers for HCC systematically.

The authors found that the combination of AFP and other biomarkers improved the diagnostic efficiency. The diagnostic value of biomarkers including DCP (PIVKA-II), GPC3, GP73, Hsp90alpha, midkine, and OPN was higher than that of AFP. GP73 had the best diagnostic value for HCC.

You May Also Like

13 September 2024

Empowering Precision Oncology: Leveraging digital solutions to facilitate molecular tumour board meetings and patient care management

Read More
19 August 2024

Pioneering Innovations in HCC Detection for Enhance Patient Outcomes – Chang Gung Memorial Hospital

Read More
19 August 2024

Strategic Efficiencies: Evaluating Cost-Effectiveness of Biomarker-Based HCC Surveillance

Read More

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.